Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma

Objectives To determine whether diffusion- and perfusion-weighted MRI–based radiomics features can improve prediction of isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in lower grade gliomas (LGGs) Methods Radiomics features ( n = 6472) were extracted from multiparametric MRI including conventional MRI, apparent diffusion coefficient (ADC), and normalized cerebral blood volume, acquired on 127 LGG patients with determined IDH mutation status and grade (WHO II or III). Radiomics models were constructed using machine learning–based feature selection and generalized linear model classifiers. Segmentation stability was calculated between two readers using concordance correlation coefficients (CCCs). Diagnostic performance to predict IDH mutation and tumor grade was compared between the multiparametric and conventional MRI radiomics models using the area under the receiver operating characteristics curve (AUC). The models were tested using a temporally independent validation set ( n = 28). Results The multiparametric MRI radiomics model was optimized with a random forest feature selector, with segmentation stability of a CCC threshold of 0.8. For IDH mutation, multiparametric MR radiomics showed similar performance (AUC 0.795) to the conventional radiomics model (AUC 0.729). In tumor grading, multiparametric model with ADC features showed higher performance (AUC 0.932) than the conventional model (AUC 0.555). The independent validation set showed the same trend with AUCs of 0.747 for IDH prediction and 0.819 for tumor grading with multiparametric MRI radiomics model. Conclusion Multiparametric MRI radiomics model showed improved diagnostic performance in tumor grading and comparable diagnostic performance in IDH mutation status, with ADC features playing a significant role. Key Points • The multiparametric MRI radiomics model was comparable with conventional MRI radiomics model in predicting IDH mutation. • The multiparametric MRI radiomics model outperformed conventional MRI in glioma grading. • Apparent diffusion coefficient played an important role in glioma grading and predicting IDH mutation status using radiomics.

[1]  G. Johnson,et al.  Relative cerebral blood volume measurements of low-grade gliomas predict patient outcome in a multi-institution setting. , 2010, European journal of radiology.

[2]  Baojuan Li,et al.  Radiomics Strategy for Molecular Subtype Stratification of Lower‐Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI , 2018, Journal of magnetic resonance imaging : JMRI.

[3]  Tin Kam Ho,et al.  The Random Subspace Method for Constructing Decision Forests , 1998, IEEE Trans. Pattern Anal. Mach. Intell..

[4]  Dafna Ben-Bashat,et al.  MRI radiomics analysis of molecular alterations in low-grade gliomas , 2018, International Journal of Computer Assisted Radiology and Surgery.

[5]  Sohil H. Patel,et al.  T2–FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project , 2017, Clinical Cancer Research.

[6]  T. Cloughesy,et al.  NIMG-24HIGH SPATIOTEMPORAL DYNAMIC SUSCEPTIBILITY CONTRAST (DSC) PERFUSION MRI USING MULTIBAND ECHOPLANAR IMAGING (MB-EPI) , 2015 .

[7]  Qiang Tian,et al.  Radiomics strategy for glioma grading using texture features from multiparametric MRI , 2018, Journal of magnetic resonance imaging : JMRI.

[8]  Glyn Johnson,et al.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. , 2004, AJNR. American journal of neuroradiology.

[9]  How Far Are We from Using Radiomics Assessment of Gliomas in Clinical Practice? , 2018, Radiology.

[10]  Hans Kristian Bø,et al.  Quantitative texture analysis in the prediction of IDH status in low-grade gliomas , 2018, Clinical Neurology and Neurosurgery.

[11]  Wei Cao,et al.  Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma , 2017, Scientific Reports.

[12]  M Takahashi,et al.  Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. , 1998, AJR. American journal of roentgenology.

[13]  Yi-bin Xi,et al.  Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging , 2018, Neuroradiology.

[14]  Marion Smits,et al.  Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. , 2015, Neuro-oncology.

[15]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[16]  Susan M. Chang,et al.  Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy , 2008, Journal of Neuro-Oncology.

[17]  Andre Dekker,et al.  Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.

[18]  Benjamin M. Ellingson,et al.  Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and Correlation with Molecular Characteristics , 2014, Current Neurology and Neuroscience Reports.

[19]  E. Shaw,et al.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Arno Klein,et al.  A reproducible evaluation of ANTs similarity metric performance in brain image registration , 2011, NeuroImage.

[21]  A. Bjørnerud,et al.  Histogram Analysis of MR Imaging–Derived Cerebral Blood Volume Maps: Combined Glioma Grading and Identification of Low-Grade Oligodendroglial Subtypes , 2008, American Journal of Neuroradiology.

[22]  Toshinori Hirai,et al.  Usefulness of diffusion‐weighted MRI with echo‐planar technique in the evaluation of cellularity in gliomas , 1999, Journal of magnetic resonance imaging : JMRI.

[23]  Yang Yang,et al.  Optimizing Texture Retrieving Model for Multimodal MR Image‐Based Support Vector Machine for Classifying Glioma , 2019, Journal of magnetic resonance imaging : JMRI.

[24]  Jong-Hee Chang,et al.  Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of IDH1-Mutation and 1p/19q-Codeletion Status in World Health Organization Grade II Gliomas , 2018, American Journal of Neuroradiology.

[25]  G. Reifenberger,et al.  European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. , 2017, The Lancet. Oncology.

[26]  C. Crainiceanu,et al.  Statistical normalization techniques for magnetic resonance imaging , 2014, NeuroImage: Clinical.

[27]  P. Lambin,et al.  Radiomics: the bridge between medical imaging and personalized medicine , 2017, Nature Reviews Clinical Oncology.

[28]  Jason Weston,et al.  Gene Selection for Cancer Classification using Support Vector Machines , 2002, Machine Learning.

[29]  A. Lagares,et al.  The Added Value of Apparent Diffusion Coefficient to Cerebral Blood Volume in the Preoperative Grading of Diffuse Gliomas , 2012, American Journal of Neuroradiology.

[30]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[31]  Chia-Feng Lu,et al.  Machine Learning–Based Radiomics for Molecular Subtyping of Gliomas , 2018, Clinical Cancer Research.

[32]  S. Y. Kim,et al.  A Prospective Study on the Added Value of Pulsed Arterial Spin-Labeling and Apparent Diffusion Coefficients in the Grading of Gliomas , 2007, American Journal of Neuroradiology.

[33]  Mitchel S Berger,et al.  Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. , 2012, Neuro-oncology.

[34]  S. Heiland,et al.  IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma , 2015, Scientific Reports.

[35]  Inas S. Khayal,et al.  Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM , 2009, Journal of Neuro-Oncology.

[36]  D. Oldridge,et al.  MRI features predict survival and molecular markers in diffuse lower-grade gliomas , 2017, Neuro-oncology.

[37]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[38]  Sung Tae Kim,et al.  Diffusion radiomics as a diagnostic model for atypical manifestation of primary central nervous system lymphoma: development and multicenter external validation , 2018, Neuro-oncology.

[39]  Usha Sinha,et al.  Relationships Between Choline Magnetic Resonance Spectroscopy, Apparent Diffusion Coefficient and Quantitative Histopathology in Human Glioma , 2000, Journal of Neuro-Oncology.

[40]  Jie Tian,et al.  Grading of Gliomas by Using Radiomic Features on Multiple Magnetic Resonance Imaging (MRI) Sequences , 2017, Medical science monitor : international medical journal of experimental and clinical research.

[41]  Winand N M Dinjens,et al.  Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Mauricio Castillo,et al.  Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. , 2007, AJR. American journal of roentgenology.

[43]  M. J. van den Bent,et al.  The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study , 2018, Neuro-oncology.

[44]  M. Götz,et al.  Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. , 2016, Radiology.

[45]  Guang Li,et al.  Gene signatures based on therapy responsiveness provide guidance for combined radiotherapy and chemotherapy for lower grade glioma , 2020, Journal of cellular and molecular medicine.

[46]  Gary S Collins,et al.  Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration , 2015, Annals of Internal Medicine.

[47]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[48]  Tarik Tihan,et al.  MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. , 2017, AJR. American journal of roentgenology.

[49]  L. Lin,et al.  A concordance correlation coefficient to evaluate reproducibility. , 1989, Biometrics.